Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.97 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.97 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL27715166 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL331331 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL67288 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9043997 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL339189 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL5961357 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL27878729 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL28325598 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115925755-A | Method for preparing cytarabine hydrochloride | 北京斯利安药业有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-108440624-B | Environment-friendly method for separating and purifying cytidine from microbial fermentation broth | 苏州华赛生物工程技术有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-108373491-B | Preparation method of nelarabine | 浙江诚意药业股份有限公司 | 2020-05-01 | — | — | CN | claimed |
| CN-108440624-A | A kind of method that environment-friendly type isolates and purifies cytidine from microbial fermentation solution | 苏州华赛生物工程技术有限公司 | 2018-08-24 | — | — | CN | claimed |
| CN-103232508-A | Industrialized gemcitabine hydrochloride synthesis method | HUBEI HALFSKY PHARMACY CO LTD | 2013-08-07 | — | — | CN | claimed |
| CN-101492482-B | Synthesis process of the industrial production of gemcitabine hydrochloride | NENGTE MEDICAL CHEMICAL TECHNOLOGY JINGZHOU CO LTD | 2010-09-29 | — | — | CN | claimed |
| CN-101792788-A | Preparation method of 5'-acylated cytidine and application in preparing medicaments for treating heart and liver diseases | ZHEN AO GROUP | 2010-08-04 | — | — | CN | claimed |
| CN-101492482-A | Synthesis process of the industrial production of gemcitabine hydrochloride | NENGTE MEDICAL CHEMICAL TECHNO (CN) | 2009-07-29 | — | — | CN | claimed |
| CN-100334101-C | Method for synthesizing 2',3'-dideoxy cytidine | FUBANG BIO PHARMACEUTICAL CO L (CN) | 2007-08-29 | — | — | CN | claimed |
| CN-1228342-C | Method of preparing 2'-deoxy-2',2'-difluoro-beta-nucleoside or its medical salt using 1,6-dehydro-beta-D-glucose as raw material | HANDESEN TECHNOLOGY CO LTD SHE (CN) | 2005-11-23 | — | — | CN | claimed |
| CN-1640883-A | Method for synthesizing 2',3'-dideoxy cytidine | FUBANG BIO PHARMACEUTICAL CO L (CN) | 2005-07-20 | — | — | CN | claimed |
| CN-1442420-A | Method of preparing 2'-deoxy-2',2'-difluoro-beta-nucleoside or its medical salt using 1,6-dehydro-beta-D-glucose as raw material | HANDESEN TECHNOLOGY CO LTD SHE (CN) | 2003-09-17 | — | — | CN | claimed |
| CN-119818525-A | Cytarabine amino acid ester composition and application thereof | 沈阳信达泰康医药科技有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| CN-119552207-A | Preparation method of 2' -deoxy-2 ',2' -difluoro-beta-nucleotidyl glycoside and intermediate and salt thereof | 江苏德迈药业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-0339075-A4 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF. | PRO NEURON INC (US) | 1990-04-10 | — | — | EP | disclosed |
| EP-0339075-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003837-A1 | ACYLATED URIDINE AND CYTIDINE AND USES THEREOF | PRO-NEURON, INC. (US) | 1989-05-05 | — | — | WO | disclosed |
| US-4145414-A | ANTIVIRAL, IMMUNOSUPPRESSIVE, ANTILEUKEMIA | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | LMNA 712/4885MTOR 1111/4885THRB 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.